-
Something wrong with this record ?
A single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models
M. Bamorovat, I. Sharifi, A. Fekri, A. Keyhani, MR. Aflatoonian, A. Heshmatkhah, RT. Oliaee, A. Khosravi, A. Naderi, MH. Parizi, M. Mostafavi, RS. Varma,
Language English Country England, Great Britain
Document type Journal Article
- MeSH
- Antiprotozoal Agents pharmacology therapeutic use MeSH
- Cell Line drug effects MeSH
- Chronic Disease therapy MeSH
- Child MeSH
- Adult MeSH
- Drug Combinations MeSH
- Interleukin-10 metabolism MeSH
- Interleukin-12 Subunit p40 metabolism MeSH
- Drug Therapy, Combination MeSH
- Leishmania tropica drug effects pathogenicity MeSH
- Leishmaniasis, Cutaneous drug therapy MeSH
- Levamisole administration & dosage pharmacology therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Macrophages drug effects MeSH
- Meglumine Antimoniate administration & dosage pharmacology therapeutic use MeSH
- Adolescent MeSH
- Young Adult MeSH
- Mice MeSH
- Aged MeSH
- Nitric Oxide Synthase Type II metabolism MeSH
- Tumor Necrosis Factor-alpha metabolism MeSH
- Transforming Growth Factor beta metabolism MeSH
- Cell Survival drug effects MeSH
- Treatment Outcome MeSH
- Animals MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Mice MeSH
- Aged MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Currently, there is no satisfactory treatment modality available for cutaneous leishmaniasis (CL). The major objective of the present study was to explore the effect of immunomodulator-levamisole in combination with Glucantime in end-stage unresponsive patients with anthroponotic CL (ACL). Twenty end-stage unresponsive patients with ACL were identified for participation in this single-group trial study. Simultaneously, each patient was received a combination of levamisole pills along with Glucantime during the remedy course. Several in vitro complementary experiments were performed to evaluate the mode of action of levamisole and Glucantime alone and in combination using a macrophage model, in vitro MTT assay, flow cytometry and quantitative real time PCR (qPCR). Overall, 75% of the patients showed complete clinical cure, 10% partially improved and the remaining (15%) had underlying chronic diseases demonstrated no response to the treatment regimen. In in vitro studies, there was no cytotoxic effect associated with these drugs in the range of our experiments. The findings by the flow cytometric analysis represented that the highest apoptotic values corresponded to the drugs combination (32.23%) at 200 μg/ml concentration. Finally, the gene expression level of IL-12 p40, iNOS and TNF-α promoted while the level of IL-10 and TGF-β genes reduced as anticipated. The findings clearly indicated that the combination of levamisole and Glucantime should be considered in end-stage unresponsive patients with ACL who have not responded to basic treatments. The immunomodulatory role of levamisole in mounting immune system as documented by the in vitro experiments and further substantiated by this single-group trail study was highlighted.
Dadbin Health Clinic Kerman University of Medical Sciences Kerman Iran
Department of Dermatology Kerman University of Medical Sciences Kerman Iran
Department of Medical Parasitology and Mycology Kerman University of Medical Sciences Kerman Iran
Leishmaniasis Research Center Kerman University of Medical Sciences Kerman Iran
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012010
- 003
- CZ-PrNML
- 005
- 20190418084552.0
- 007
- ta
- 008
- 190405s2019 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.micpath.2018.12.040 $2 doi
- 035 __
- $a (PubMed)30583021
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Bamorovat, Mehdi $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
- 245 12
- $a A single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models / $c M. Bamorovat, I. Sharifi, A. Fekri, A. Keyhani, MR. Aflatoonian, A. Heshmatkhah, RT. Oliaee, A. Khosravi, A. Naderi, MH. Parizi, M. Mostafavi, RS. Varma,
- 520 9_
- $a Currently, there is no satisfactory treatment modality available for cutaneous leishmaniasis (CL). The major objective of the present study was to explore the effect of immunomodulator-levamisole in combination with Glucantime in end-stage unresponsive patients with anthroponotic CL (ACL). Twenty end-stage unresponsive patients with ACL were identified for participation in this single-group trial study. Simultaneously, each patient was received a combination of levamisole pills along with Glucantime during the remedy course. Several in vitro complementary experiments were performed to evaluate the mode of action of levamisole and Glucantime alone and in combination using a macrophage model, in vitro MTT assay, flow cytometry and quantitative real time PCR (qPCR). Overall, 75% of the patients showed complete clinical cure, 10% partially improved and the remaining (15%) had underlying chronic diseases demonstrated no response to the treatment regimen. In in vitro studies, there was no cytotoxic effect associated with these drugs in the range of our experiments. The findings by the flow cytometric analysis represented that the highest apoptotic values corresponded to the drugs combination (32.23%) at 200 μg/ml concentration. Finally, the gene expression level of IL-12 p40, iNOS and TNF-α promoted while the level of IL-10 and TGF-β genes reduced as anticipated. The findings clearly indicated that the combination of levamisole and Glucantime should be considered in end-stage unresponsive patients with ACL who have not responded to basic treatments. The immunomodulatory role of levamisole in mounting immune system as documented by the in vitro experiments and further substantiated by this single-group trail study was highlighted.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antiprotozoální látky $x farmakologie $x terapeutické užití $7 D000981
- 650 _2
- $a buněčné linie $x účinky léků $7 D002460
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a chronická nemoc $x terapie $7 D002908
- 650 _2
- $a fixní kombinace léků $7 D004338
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interleukin-10 $x metabolismus $7 D016753
- 650 _2
- $a interleukin-12 - podjednotka p40 $x metabolismus $7 D053762
- 650 _2
- $a Leishmania tropica $x účinky léků $x patogenita $7 D007895
- 650 _2
- $a leishmanióza kožní $x farmakoterapie $7 D016773
- 650 _2
- $a levamisol $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D007978
- 650 _2
- $a makrofágy $x účinky léků $7 D008264
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a meglumin antimoniát $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D000077485
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a synthasa oxidu dusnatého, typ II $x metabolismus $7 D052247
- 650 _2
- $a transformující růstový faktor beta $x metabolismus $7 D016212
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a TNF-alfa $x metabolismus $7 D014409
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sharifi, Iraj $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran. Electronic address: iraj.sharifi@yahoo.com.
- 700 1_
- $a Fekri, Alireza $u Department of Dermatology, Kerman University of Medical Sciences, Kerman, Iran.
- 700 1_
- $a Keyhani, Alireza $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
- 700 1_
- $a Aflatoonian, Mohammad Reza $u Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran.
- 700 1_
- $a Heshmatkhah, Amireh $u Dadbin Health Clinic, Kerman University of Medical Sciences, Kerman, Iran.
- 700 1_
- $a Oliaee, Razieh Tavakoli $u Department of Medical Parasitology and Mycology, Kerman University of Medical Sciences, Kerman, Iran.
- 700 1_
- $a Khosravi, Ahmad $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
- 700 1_
- $a Naderi, Afsaneh $u Department of Medical Parasitology and Mycology, Kerman University of Medical Sciences, Kerman, Iran.
- 700 1_
- $a Parizi, Maryam Hakimi $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
- 700 1_
- $a Mostafavi, Mahshid $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
- 700 1_
- $a Varma, Rajender S $u Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacký University in Olomouc, Šlechtitelů 27, 783 71, Olomouc, Czech Republic.
- 773 0_
- $w MED00008641 $t Microbial pathogenesis $x 1096-1208 $g Roč. 128, č. - (2019), s. 162-170
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30583021 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190418084620 $b ABA008
- 999 __
- $a ok $b bmc $g 1391320 $s 1050315
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 128 $c - $d 162-170 $e 20181221 $i 1096-1208 $m Microbial pathogenesis $n Microb Pathog $x MED00008641
- LZP __
- $a Pubmed-20190405
